Progyny [PGNY] vs Cigna [CI] Detailed Stock Comparison
Progyny
NASDAQ
Loading...
Cigna
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Progyny wins in 7 metrics, Cigna wins in 11 metrics, with 0 ties. Cigna appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Progyny | Cigna | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 38.54 | 16.28 | Cigna |
| Price-to-Book Ratio | 3.77 | 1.97 | Cigna |
| Debt-to-Equity Ratio | 5.56 | 76.10 | Progyny |
| PEG Ratio | 3.47 | 9.48 | Progyny |
| EV/EBITDA | 20.78 | 9.21 | Cigna |
| Profit Margin (TTM) | 4.28% | 1.92% | Progyny |
| Operating Margin (TTM) | 7.32% | 3.67% | Progyny |
| EBITDA Margin (TTM) | 7.32% | 3.67% | Progyny |
| Return on Equity | 10.94% | 13.18% | Cigna |
| Return on Assets (TTM) | 6.57% | 3.98% | Progyny |
| Free Cash Flow (TTM) | $173.70M | $8.96B | Cigna |
| Dividend Yield | N/A | 1.37% | N/A |
| 1-Year Return | 6.10% | -14.98% | Progyny |
| Price-to-Sales Ratio (TTM) | 1.57 | 0.30 | Cigna |
| Enterprise Value | $1.68B | $105.08B | Cigna |
| EV/Revenue Ratio | 1.35 | 0.40 | Cigna |
| Gross Profit Margin (TTM) | 23.72% | N/A | N/A |
| Revenue per Share (TTM) | $14 | $961 | Cigna |
| Earnings per Share (Diluted) | $0.59 | $18.23 | Cigna |
| Beta (Stock Volatility) | 1.33 | 0.48 | Cigna |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Progyny vs Cigna Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Progyny | 2.53% | 2.57% | 0.83% | 9.16% | -0.30% | 30.46% |
| Cigna | -1.19% | 3.65% | 2.09% | -5.09% | 0.38% | 9.64% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Progyny | 6.10% | -44.49% | -19.10% | 45.11% | 45.11% | 45.11% |
| Cigna | -14.98% | 5.64% | 66.13% | 118.29% | 825.43% | 700.40% |
Performance & Financial Health Analysis: Progyny vs Cigna
| Metric | PGNY | CI |
|---|---|---|
| Market Information | ||
| Market Cap | $1.96B | $79.24B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,385,600 | 2,081,340 |
| 90 Day Avg. Volume | 1,083,093 | 1,899,187 |
| Last Close | $23.13 | $300.95 |
| 52 Week Range | $13.39 - $26.76 | $256.89 - $370.83 |
| % from 52W High | -13.57% | -18.84% |
| All-Time High | $68.32 (Nov 01, 2021) | $370.83 (Sep 16, 2024) |
| % from All-Time High | -66.14% | -18.84% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.11% |
| Quarterly Earnings Growth | 0.04% | -0.01% |
| Financial Health | ||
| Profit Margin (TTM) | 0.04% | 0.02% |
| Operating Margin (TTM) | 0.07% | 0.04% |
| Return on Equity (TTM) | 0.11% | 0.13% |
| Debt to Equity (MRQ) | 5.56 | 76.10 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.04 | $150.84 |
| Cash per Share (MRQ) | $3.55 | $19.26 |
| Operating Cash Flow (TTM) | $202.00M | $5.29B |
| Levered Free Cash Flow (TTM) | $194.61M | $4.47B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.37% |
| Last 12-Month Dividend | N/A | $4.31 |
Valuation & Enterprise Metrics Analysis: Progyny vs Cigna
| Metric | PGNY | CI |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 38.54 | 16.28 |
| Forward P/E | 29.92 | 9.48 |
| PEG Ratio | 3.47 | 9.48 |
| Price to Sales (TTM) | 1.57 | 0.30 |
| Price to Book (MRQ) | 3.77 | 1.97 |
| Market Capitalization | ||
| Market Capitalization | $1.96B | $79.24B |
| Enterprise Value | $1.68B | $105.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.35 | 0.40 |
| Enterprise to EBITDA | 20.78 | 9.21 |
| Risk & Other Metrics | ||
| Beta | 1.33 | 0.48 |
| Book Value per Share (MRQ) | $6.04 | $150.84 |
Financial Statements Comparison: Progyny vs Cigna
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PGNY | CI |
|---|---|---|
| Revenue/Sales | $332.87M | $67.23B |
| Cost of Goods Sold | $253.90M | N/A |
| Gross Profit | $78.97M | N/A |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $24.36M | N/A |
| EBITDA | $25.56M | N/A |
| Pre-Tax Income | $27.08M | $2.02B |
| Income Tax | $9.97M | $389.00M |
| Net Income (Profit) | $17.11M | $1.63B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PGNY | CI |
|---|---|---|
| Cash & Equivalents | $109.24M | $8.33B |
| Total Current Assets | $567.69M | N/A |
| Total Current Liabilities | $237.13M | N/A |
| Long-Term Debt | $26.00M | $26.46B |
| Total Shareholders Equity | $467.16M | $40.41B |
| Retained Earnings | $159.37M | $44.43B |
| Property, Plant & Equipment | $42.69M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PGNY | CI |
|---|---|---|
| Operating Cash Flow | $27.84M | $-493.00M |
| Capital Expenditures | $-2.84M | $-327.00M |
| Free Cash Flow | $46.97M | $1.59B |
| Debt Repayment | N/A | $-700.00M |
| Common Stock Repurchase | $0 | $-1.51B |
Short Interest & Institutional Ownership Analysis
| Metric | PGNY | CI |
|---|---|---|
| Shares Short | 7.76M | 2.45M |
| Short Ratio | 7.47 | 1.30 |
| Short % of Float | 0.12% | 0.01% |
| Average Daily Volume (10 Day) | 1,385,600 | 2,081,340 |
| Average Daily Volume (90 Day) | 1,083,093 | 1,899,187 |
| Shares Outstanding | 85.31M | 273.79M |
| Float Shares | 79.61M | 265.64M |
| % Held by Insiders | 0.08% | 0.02% |
| % Held by Institutions | 1.04% | 0.90% |
Dividend Analysis & Yield Comparison: Progyny vs Cigna
| Metric | PGNY | CI |
|---|---|---|
| Last 12-Month Dividend | N/A | $4.31 |
| Last 12-Month Dividend Yield | N/A | 1.37% |
| 3-Year Avg Annual Dividend | N/A | $4.35 |
| 3-Year Avg Dividend Yield | N/A | 0.42% |
| 3-Year Total Dividends | N/A | $13.04 |
| Ex-Dividend Date | N/A | Mar 05, 2025 |